North American Autoimmune Disease Diagnostics Market revenue to reach $600 Mn by 2028

Published Date: 2022-09-05

Request a sample

North American Autoimmune Disease Diagnostics Market size is predicted to cross USD 600 million by 2028, according to a latest forecast report by Graphical Research.

Rising adoption of effective and rapid screening methods will foster the uptake of autoimmune diagnostic tests over the next few years in North America. Since the COVID-19 pandemic, a substantial number of regional hospitals have been upgrading their lab equipment. Several healthcare services providers are embracing lab automation technologies to streamline workflows, enhance turnaround time, and maximize profits.

Over 50 million individuals in the U.S. suffer from autoimmune diseases, revealing the urgency to address the cost burden associated with these conditions. Since 2020, research activities around autoimmune conditions have increased considerably. Recent studies by Arthritis Research Canada have revealed that individuals living with rheumatic diseases as well as transplant recipients faced a higher risk of COVID-19-related complications and mortality. Rising incidence of these conditions will fuel the demand for blood tests to detect autoimmune disorders.

Researchers have recently evaluated COVID-19 hospitalizations, ventilation, intensive care admissions, as well as mortality rate of individuals with different types of arthritis, identifying a 30% higher risk of ICU admissions and hospitalization. These individuals also had a 60% more risk of being on a ventilator than average patients. Owing to the growing concerns amongst regional population regarding negative health outcomes linked with these conditions, the government has been investing in R&D.

The North America autoimmune disease diagnostics market share from the localized autoimmune disease segment accounted for USD 260 million revenue in 2021. Since the last few years, the incidence of multiple sclerosis (MS), Addison’s disease, Graves’ disease, celiac disease, and autoimmune hepatitis, among other localized autoimmune disorders, has been growing across Canada and the U.S. According to the Multiple Sclerosis Association of America (MSAA), over one million people in the U.S. are living with MS.

Browse detailed statistical insights from the report, “North America Autoimmune Disease Diagnostics Market Forecast 2028 By Test Type (Antinuclear Antibody Tests, Autoantibody Tests, C-reactive Protein (CRP), Complete Blood Count (CBC), Urinalysis), By Product (Systemic Autoimmune Disease {Rheumatoid arthritis, Ankylosing spondylitis, Systemic Lupus Erythematosus}, Localized Autoimmune Disease), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @

Canada autoimmune disease diagnostics market size will witness 7% CAGR from 2022 to 2028, attributed to the rising prevalence of rheumatoid arthritis will ensure a steady adoption of diagnostic tests for autoimmune disorders. More than 374,000 Canadians aged 16 and up are currently living rheumatoid arthritis.

Several diagnostic testing centers in Canada have been focusing on providing best-in-class autoimmune disease screening tests at affordable prices. Since clinical decision making relies heavily on diagnostics in the present-day patient care management, several laboratories across Alberta are migrating to a centralized testing and processing of lab tests.

In March 2022, for instance, Alberta Health Services (AHS) announced its partnership with Roche Diagnostics for delivering high quality patient care through improved lab equipment. Roche’s new solutions will be deployed across provincial lab sites in Lethbridge, Red Deer, Calgary, Grand Prairie, and Medicine Hat. Along similar lines, the government of Alberta announced that it will invest over USD 21.1 billion toward the upgradation of laboratory equipment across Edmonton and norther Alberta.

North American autoimmune disease diagnostics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2017 to 2028, for the following segments:

North America Market, By Disease Type

  • Systemic Autoimmune Disease
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus (SLE)
    • Psoriasis
    • Multiple Sclerosis
    • Others
  • Localized Autoimmune Disease      
    • Inflammatory Bowel Disease
    • Type 1 Diabetes
    • Thyroid
    • Others

North America Market, By Test Type

  • Antinuclear Antibody Tests
  • Autoantibody Tests
  • C-reactive Protein (CRP)
  • Complete Blood Count (CBC)
  • Urinalysis
  • Others

The above information has been provided for the following countries:

  • North America
    • U.S.
    • Canada